Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.
2.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
3.
Prior authorizations draining time, energy from many cancer patients
4.
Team finds broken 'brake' on cancer mutation machine.
5.
Ketamine plus psychotherapy for "excellent" PTSD
1.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
2.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
3.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
4.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
5.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
4.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation